Sartorius AG (SSSGY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sartorius AG (SSSGY) trades at $43.93 with AI Score 51/100 (Grade B). Sartorius AG is a leading international partner of the biopharmaceutical industry and laboratories. Market cap: $15.17B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for SSSGY: SSSGY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SSSGY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SSSGY: 2/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Sartorius AG (SSSGY) Healthcare & Pipeline Overview
Sartorius AG, a German-based company, provides bioprocess solutions and lab products, serving the biopharmaceutical industry and research labs globally. With a focus on innovative technologies for drug development and manufacturing, Sartorius competes with companies like ALBBY and BDUUY in the medical instruments and supplies sector, demonstrating a commitment to advancing life sciences.
What Is the Investment Thesis for SSSGY?
Sartorius AG presents a notable research candidate within the bioprocessing and lab solutions sector. With a current P/E ratio of 92.2 and a profit margin of 4.4%, the company's growth is underpinned by the increasing demand for biopharmaceutical products and advanced laboratory technologies. Key value drivers include the expansion of its product portfolio, strategic acquisitions, and penetration into emerging markets. Upcoming catalysts include the continued development of innovative bioprocessing solutions and expansion of services. Potential risks include intense competition, currency fluctuations, and regulatory changes in the healthcare sector. The company's high beta of 1.51 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
SSSGY Key Highlights
- Market capitalization of $15.17B reflects Sartorius AG's significant presence in the bioprocessing and lab solutions market.
- A P/E ratio of 92.2 indicates a premium valuation, potentially reflecting investor expectations of future growth.
- Gross margin of 46.3% demonstrates the company's ability to maintain profitability in a competitive market.
- Dividend yield of 0.35% provides a modest income stream for investors.
- Beta of 1.51 suggests higher volatility compared to the market, potentially offering higher returns but also greater risk.
Who Are SSSGY's Competitors?
SSSGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBBY Alibaba Health Information Technology Limited | $8.00 | +0.00% | $6.45B | 46 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| BDUUY Bangkok Dusit Medical Services Public Company Limited | $25.24 | +7.84% | $10.03B | 42 |
| BMXMF bioMérieux S.A. | $77.00 | -1.19% | $9.09B | 52 |
| CHEOF Cochlear Limited | $81.42 | +0.00% | $5.32B | 54 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SSSGY's Key Strengths?
- Strong market position in bioprocessing and lab solutions.
- Comprehensive product portfolio and service offerings.
- Global presence and distribution network.
- Technological expertise and innovation capabilities.
What Are SSSGY's Weaknesses?
- High P/E ratio may indicate overvaluation.
- Profit margin could be higher compared to industry leaders.
- Dependence on the biopharmaceutical industry.
What Could Drive SSSGY Stock Higher?
- Increasing demand for biopharmaceuticals driving growth in bioprocessing solutions.
- Expansion of product portfolio through strategic acquisitions and innovation.
- Potential regulatory approvals for new biopharmaceutical products utilizing Sartorius's technologies.
- Growing adoption of single-use technologies in biomanufacturing.
- Development and launch of new data analytics platforms for bioprocessing.
What Are the Key Risks for SSSGY?
- Rich valuation — a P/E of 92.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Intense competition from established players in the bioprocessing and lab solutions market.
- Regulatory changes in the healthcare sector affecting biopharmaceutical manufacturing.
- Currency fluctuations impacting revenue and profitability.
- Economic downturns affecting the biopharmaceutical industry.
- Dependence on key customers and suppliers.
What Are the Growth Opportunities for SSSGY?
- Expansion into Emerging Markets: Sartorius AG has the opportunity to expand its presence in emerging markets, such as Asia-Pacific and Latin America, where the demand for biopharmaceuticals and advanced laboratory technologies is growing rapidly. This expansion could involve establishing new sales offices, distribution networks, or manufacturing facilities. The market size for biopharmaceuticals in emerging markets is projected to reach $200 billion by 2028, presenting a significant growth opportunity for Sartorius. Timeline: Ongoing.
- Development of Innovative Bioprocessing Solutions: Investing in the development of innovative bioprocessing solutions, such as advanced bioreactors, filtration systems, and chromatography products, can drive growth for Sartorius AG. These solutions can improve bioprocessing efficiency, reduce costs, and enhance product quality. The market for bioprocessing technologies is expected to reach $30 billion by 2027, driven by the increasing demand for biopharmaceuticals. Timeline: Ongoing.
- Strategic Acquisitions: Sartorius AG can pursue strategic acquisitions to expand its product portfolio, enter new markets, or gain access to new technologies. Acquisitions can provide synergies and accelerate growth. The company has a history of successful acquisitions, such as the acquisition of Novasep's chromatography division in 2021. Timeline: Ongoing.
- Increased Focus on Data Analytics and Automation: The integration of data analytics and automation into bioprocessing workflows can improve efficiency, reduce costs, and enhance product quality. Sartorius AG can invest in the development of data analytics platforms and automation solutions to meet the growing demand for these technologies. The market for data analytics in biopharmaceutical manufacturing is projected to reach $5 billion by 2028. Timeline: Ongoing.
- Expansion of Service Offerings: Sartorius AG can expand its service offerings, such as bioprocess development, engineering, and validation services, to provide comprehensive solutions to its customers. These services can generate recurring revenue and strengthen customer relationships. The market for bioprocessing services is expected to reach $15 billion by 2027, driven by the increasing complexity of biopharmaceutical manufacturing. Timeline: Ongoing.
What Opportunities Does SSSGY Have?
- Expansion into emerging markets.
- Development of innovative bioprocessing solutions.
- Strategic acquisitions to expand product portfolio.
- Increased focus on data analytics and automation.
What Threats Does SSSGY Face?
- Intense competition from established players.
- Regulatory changes in the healthcare sector.
- Currency fluctuations.
- Economic downturns affecting the biopharmaceutical industry.
What Are SSSGY's Competitive Advantages?
- Strong brand reputation and established customer relationships.
- Extensive product portfolio and comprehensive solutions.
- Technological expertise and innovation capabilities.
- Global presence and distribution network.
What Does SSSGY Do?
Founded in 1870 and headquartered in Göttingen, Germany, Sartorius AG has evolved into a leading provider of bioprocess solutions and lab products and services. The company supports the biopharmaceutical industry and research laboratories worldwide, offering a comprehensive portfolio of products and services designed to optimize bioprocessing workflows and laboratory operations. Sartorius's offerings include biosensors and kits, compliance tools, systems software, and a range of bioreactors, from multi-parallel to single-use and stainless steel models. They also provide filtration equipment, membranes, chromatography products, and fluid management solutions. Sartorius serves a diverse range of industries, including life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. Its global presence and diverse product portfolio have solidified its position as a key player in the bioprocessing and lab solutions market, competing with companies like ALBBY and CHEOF.
What Products and Services Does SSSGY Offer?
- Provides biosensors and kits for bioprocess monitoring.
- Offers compliance tools and systems software for regulated industries.
- Develops and manufactures bioreactors for cell culture and microbial fermentation.
- Supplies membranes, filters, and filtration equipment for bioprocessing.
- Provides chromatography products for protein purification.
- Offers fluid management products for biopharmaceutical manufacturing.
- Develops process analytical technology and data analytics solutions.
- Provides services such as bioprocess development and validation.
How Does SSSGY Make Money?
- Sartorius AG generates revenue through the sale of bioprocess solutions and lab products.
- The company also generates revenue through service offerings, such as bioprocess development and validation.
- Recurring revenue is generated through the sale of consumables, such as filters and media.
- The company invests in research and development to develop innovative products and solutions.
What Industry Does SSSGY Operate In?
Sartorius AG operates within the rapidly growing bioprocessing and lab solutions market, driven by the increasing demand for biopharmaceuticals and advanced research technologies. The industry is characterized by intense competition, with key players like ALBBY and BDUUY vying for market share. Trends include the adoption of single-use technologies, automation, and data analytics to improve bioprocessing efficiency and reduce costs. The company's focus on innovation and strategic acquisitions positions it well to capitalize on these trends and maintain its competitive edge.
Who Are SSSGY's Key Customers?
- Biopharmaceutical companies involved in drug development and manufacturing.
- Life science research laboratories.
- Quality control and testing laboratories.
- Applied industries, such as food and beverage.
Sartorius AG (SSSGY) Valuation Context
Valued at $15.17B, SSSGY is classified as a large-cap stock. Relative to its peer group, SSSGY's quantitative score of 51/100 is roughly in line with the peer average of 48/100.
SSSGY Revenue & Earnings Trend
In Q1 2026, SSSGY generated $913.9M in top-line revenue, marking a sequential decrease of 0.5%. The company recorded net income of $57.1M, with diluted EPS of $0.17. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SSSGY averaged $0.12 in diluted EPS.
Company Profile
Sartorius AG operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Göttingen, DE. The company is led by CEO Michael Grosse. SSSGY has traded publicly since 2021.
ROE 6%Key Financial Metrics
Return on equity for Sartorius AG stands at 6.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.6%, showing how much profit it generates from its asset base. SSSGY trades at a trailing price-to-earnings ratio of 92.18, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.91 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 1.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Sartorius AG's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.20 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Sartorius AG revenue of about $3.75B for fiscal 2026, with EPS near $0.00. The estimate reflects 22 contributing analysts.
SSSGY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market position in bioprocessing and lab solutions.
- Comprehensive product portfolio and service offerings.
- Global presence and distribution network.
- Technological expertise and innovation capabilities.
Bear Case
- High P/E ratio may indicate overvaluation.
- Profit margin could be higher compared to industry leaders.
- Dependence on the biopharmaceutical industry.
- Potential: Intense competition from established players in the bioprocessing and lab solutions market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $914M | $57M | $0.17 |
| Q4 2025 | $919M | $30M | $0.09 |
| Q3 2025 | $841M | $44M | $0.13 |
| Q2 2025 | $884M | $33M | $0.09 |
Based on FMP financials and quantitative analysis
SSSGY Latest News
No recent news available for SSSGY.
SSSGY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SSSGY.
Price Targets
Wall Street price target analysis for SSSGY.
SSSGY MoonshotScore
What does this score mean?
The MoonshotScore rates SSSGY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Grosse
CEO
Michael Grosse serves as the CEO of Sartorius AG, leading a global workforce of 13,573 employees. His career spans various leadership roles in the technology and manufacturing sectors. He has a strong background in strategic management and operational excellence. His expertise lies in driving growth through innovation and market expansion, with a focus on customer-centric solutions. He brings extensive experience in leading multinational organizations and fostering a culture of collaboration and performance.
Track Record: Under Michael Grosse's leadership, Sartorius AG has experienced significant growth and expansion, marked by strategic acquisitions and increased market share. He has overseen the development and launch of innovative bioprocessing solutions, strengthening the company's competitive position. His tenure has been characterized by a focus on operational efficiency and customer satisfaction, contributing to improved financial performance and enhanced shareholder value.
Sartorius AG ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. SSSGY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without requiring the same level of regulatory compliance as listed stocks. This allows U.S. investors to invest in Sartorius AG more easily.
- Home Market Ticker: Frankfurt Stock Exchange (FWB), Germany
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SSSG
SSSGY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier have minimal listing requirements and may not be required to provide audited financial statements. This tier is often associated with higher risk and less transparency compared to higher-tier OTCQX and OTCQB markets, or exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity can make it difficult to buy or sell shares at desired prices.
- Lack of transparency due to limited financial disclosures.
- Potential for price manipulation and fraud.
- Higher volatility compared to exchange-listed stocks.
- Regulatory risks associated with the OTC market.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor.
- Established business operations and track record.
- Membership in industry associations.
- Positive media coverage and analyst reports.
- Partnerships with reputable companies.
- Experienced management team.
Sartorius AG Healthcare Stock: Key Questions Answered
What does Sartorius AG do?
Sartorius AG is a leading international partner of the biopharmaceutical industry and laboratories, providing bioprocess solutions and lab products and services. The company offers a comprehensive portfolio of products and services designed to optimize bioprocessing workflows and laboratory operations, including bioreactors, filtration systems, chromatography products, and data analytics solutions. Sartorius serves a diverse range of industries, including life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries, supporting the development and manufacturing of medications and research activities worldwide.
What do analysts say about SSSGY stock?
Analyst consensus on SSSGY stock is mixed, with some analysts highlighting the company's strong market position and growth potential, while others express concerns about its high valuation and competitive landscape. Key valuation metrics, such as the P/E ratio, are above the industry average, reflecting investor expectations of future growth. Growth considerations include the company's ability to expand its product portfolio, penetrate emerging markets, and capitalize on the increasing demand for biopharmaceuticals. However, potential risks include intense competition, regulatory changes, and currency fluctuations.
What are the main risks for SSSGY?
The main risks for SSSGY include intense competition from established players in the bioprocessing and lab solutions market, regulatory changes in the healthcare sector affecting biopharmaceutical manufacturing, currency fluctuations impacting revenue and profitability, economic downturns affecting the biopharmaceutical industry, and dependence on key customers and suppliers. The company's high P/E ratio also presents a risk, as it may indicate overvaluation and vulnerability to market corrections. Additionally, the OTC market carries inherent risks related to liquidity and transparency.
What are the key factors to evaluate for SSSGY?
Sartorius AG (SSSGY) holds an AI score of 51/100 (moderate). P/E: 92.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SSSGY data refresh on this page?
SSSGY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SSSGY's recent stock price performance?
Sartorius AG (SSSGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in bioprocessing and lab solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SSSGY overvalued or undervalued right now?
Sartorius AG (SSSGY) trades at 92.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SSSGY?
Before investing in Sartorius AG (SSSGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.